ASCO Presentation Points to Clinically Relevant Mutations in Subset of Biliary Tract Tumors | GenomeWeb

CHICAGO (GenomeWeb) – A study presented at this week's American Society of Clinical Oncology annual meeting may have uncovered clinically actionable mutations in a significant subset of difficult-to-treat, advanced biliary cancers tested by targeted sequencing. 

Milind Javle, a gastrointestinal medical oncology researcher with the University of Texas MD Anderson Cancer Center, presented the work and shared vignettes about biliary tract cancer cases in which treatment was targeted based on the mutations identified. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.